Valuing R&D Projects in a Portfolio: Evidence from the Pharmaceutical Industry

References

• Adler P. S., Mandelbaum A., Nguyen V., Schwerer E. From project to process management: An empirically based framework for analyzing product development time. Management Sci. (1995) 41:458–484Link, Google Scholar
• Bayus B. L., Erickson G., Jacobson R. The financial rewards of new product introductions in the personal computer industry. Management Sci. (2003) 49:197–210Link, Google Scholar
• Belsley D. E., Kuh E., Welsch R.Regression Diagnostics: Identifying Influential Data and Sources of Collinearity (1980) (John Wiley & Sons, New York) Crossref, Google Scholar
• Brown S. J., Warner J. B. Measuring stock price performance. J. Financial Econom. (1980) 8:205–258Crossref, Google Scholar
• Chaney P. K., Devinney T. M. The impact of new product introductions on market value of firms. J. Bus. Finance Accounting (1992) 19:677–695Crossref, Google Scholar
• Chaney P. K., Devinney T. M., Winer R. S. The impact of new product introductions on the market value of firms. J. Bus. (1991) 64:573–610Crossref, Google Scholar
• Chen S. S., Ho K. W., Ik K. H. The wealth effect of new product introductions on industry rivals. J. Bus. (2005a) 78:969–996Crossref, Google Scholar
• Chen S. S., Chung T. Y., Ho K. W., Lee C. F. Intra-industry effects of delayed new product introductions. (2005b) . Working paper, National Taiwan University, College of Management, Taipei, TaiwanGoogle Scholar
• Corbett C. J., Montes-Sancho M. J., Kirsch D. A. The financial impact of ISO 9000 certification in the United States: An empirical analysis. Management Sci. (2005) 51:1046–1059Link, Google Scholar
• Dahan E., Mendelson H. An extreme value model of concept testing. Management Sci. (2001) 47:102–116Link, Google Scholar
• Danzon P. M., Nicholson S., Pereira N. S. Productivity in pharmaceutical-biotechnology R&D: The role of experience and alliances. J. Health Econom. (2005) 24:317–339Crossref, Google Scholar
• Ding M., Eliashberg J. Structuring the new product development pipeline. Management Sci. (2002) 48:343–363Link, Google Scholar
• Girotra K., Terwiesch C., Ulrich K. T. (2004) . New drug development at Merck & Co., Wharton School Teaching Case, Philadelphia, PA.Google Scholar
• Hendricks K. B., Singhal V. R. Delays in new product introductions and the market value of the firm: The consequences of being late to the market. Management Sci. (1997) 43:422–436Link, Google Scholar
• Hendricks K. B., Singhal V. R. Association between supply chain glitches and operating performance. Management Sci. (2005) 51:695–711Link, Google Scholar
• Kavadias S., Loch C. H.Project Selection Under Uncertainty: Dynamically Allocating Resources to Maximize Value (2003) (Kluwer Academic Press, Boston, MA) Google Scholar
• Kothari S. P., Warner J. B., Espen Eckbo B. Econometrics of event studies. Handbook of Corporate Finance. (2007) (Elsevier/North-Holland, Amsterdam, The Netherlands) Google Scholar
• Landers P., Lublin J. S. Under a microscope: Merck's big bet on research by its scientists comes up short. Wall Street J. (2003) November 28):A1Google Scholar
• Loch C. H., Kavadias S. Dynamic portfolio selection of NPD programs using marginal return. Management Sci. (2002) 48:1227–1241Link, Google Scholar
• Loch C. H., Terwiesch C. Accelerating the process of engineering change orders: Capacity and congestion effects. J. Product Innovation Management (1999) 16:145–159Crossref, Google Scholar
• Loch C. H., Terwiesch C., Thomke S. Parallel and sequential testing of design alternatives. Management Sci. (2001b) 47:663–678Link, Google Scholar
• Loch C. H., Pich M. T., Terwiesch C., Urbschat M. Selecting R&D projects at BMW: A case study of adopting mathematical programming models. IEEE Trans. Engrg. Management (2001a) 48:70–80Crossref, Google Scholar
• Lucas R. Optimal management of a research and development project. Management Sci. (1971) 17:679–697Link, Google Scholar
• MacKinlay C. A. Event studies in economics and finance. J. Econom. Literature (1997) 35:13–39Google Scholar
• Nicholson S., Danzon P. M., Mccullough J. Biotech-pharmaceutical alliances as a signal of asset and firm quality. J. Bus. (2005) 78:1433–1464Crossref, Google Scholar
• ParexelPAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook (2002/2003) (Parexel, Waltham, PA) Google Scholar
• Patell J. M. Corporate forecasts of earning per share and stock price behavior: Empirical tests. J. Accounting Res. (1976) 14:246–274Crossref, Google Scholar
• Pisano G. P., Rossi S. Eli Lilly and Co.: The flexible facility decision–1993. (1994) . HBS Case 9-694-074, Harvard Business School, Boston, MA.Google Scholar
• Robertson T. S., Eliashberg J., Rymon T. New product announcement signals and incumbent reactions. J. Marketing (1995) 59:1–15Crossref, Google Scholar
• Shane S. A., Ulrich K. T. Technological innovation, product development, and entrepreneurship in Management Science. Management Sci. (2004) 50:133–144Link, Google Scholar
• Sharma A., Lacey N. Linking product development outcomes to market valuation of the firm: The case of the US pharmaceutical industry. J. Product Innovation Management (2004) 21:297–308Crossref, Google Scholar
• Singhal V. R. Excess inventory and long-term stock price performance. (2005) . Working paper, Georgia Institute of Technology, Atlanta, GA.Google Scholar
• Sprent P.Applied Nonparametric Statistical Methods (1989) (Chapman and Hall, London, UK) Google Scholar
• Tkac P. A. A trading volume benchmark: Theory and evidence. J. Financial Quant. Anal. (1999) 34:89–114Crossref, Google Scholar